Inclusion Criteria:

- diagnosed with stage I-IV ovarian, peritoneal or fallopian tube cancer

- completed first-line taxane and platinum-based chemotherapy 1-4 months prior to being
enrolled in the study (can be on bevacizumab maintenance)

- in remission of their disease at the time of enrollment between 21 and 70 years of
age

- fluent in English

- in the judgment of the consenting professional, have capacity to give consent

Healthy Control

Inclusion Criteria:

- no diagnosis of cancer except basal cell carcinoma

- between 21 and 70 years of age

- fluent in English

- has a mini-mental state exam (MMSE) score of 26 or higher

- in the judgment of the consenting professional, have capacity to give consent

Exclusion Criteria:

- active or recurrent disease, or diagnosis of another cancer (except basal cell
carcinoma) as per medical records at the time of enrollment

- exposure to chemotherapy or radiation therapy for any medical condition unrelated to
ovarian cancer

- on hormonal therapy at the time of enrollment

- neurological disorder or moderate to severe head trauma (loss of consciousness > 60
min)

- neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease,
multiple sclerosis, etc.

- self-reported Axis I psychiatric disorder (DSM-IV), major affective disorder
(untreated), bipolar disorder, schizophrenia

- unable to complete cognitive tests

- with standard contraindications to MRI examinations

Healthy Control Exclusion Criteria:

- exposure to chemotherapy or radiation therapy for any medical condition

- on hormone replacement therapy at the time of enrollment

- neurological disorder or moderate to severe head trauma (loss of consciousness > 60
min)

- neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease,
multiple sclerosis, etc.